Visfatin Induces Inflammation and Insulin Resistance via the NF-κB and STAT3 Signaling Pathways in Hepatocytes

Visfatin induces the apoptosis of endothelial progenitor cells via the induction of pro-inflammatory mediators through the NF-κB pathway

(2017) Lina Sun et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Visfatin triggers the in vitro migration of osteosarcoma cells via activation of NF-κB/IL-6 signals

(2016) Guang-Ji Wang et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome

(2015) Mitra Nourbakhsh et al.   SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION

Visfatin contributes to the differentiation of monocytes into macrophages through the differential regulation of inflammatory cytokines in THP-1 cells

(2014) Mi Ran Yun et al.   CELLULAR SIGNALLING

Extracellular Visfatin Activates Gluconeogenesis in HepG2 Cells Through the Classical PKA/CREB-Dependent Pathway

(2014) Y. Choi et al.   HORMONE AND METABOLIC RESEARCH

The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer

(2014) SHU-WEI WANG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Visfatin/NAMPT: A Multifaceted Molecule with Diverse Roles in Physiology and Pathophysiology

(2012) Tuva B. Dahl et al.   Annual Review of Nutrition

Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease

(2012) Teresa Auguet et al.   CLINICAL BIOCHEMISTRY

Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review

(2011) Yu-Hung Chang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Visfatin/PBEF/Nampt induces EMMPRIN and MMP-9 production in macrophages via the NAMPT-MAPK (p38, ERK1/2)-NF-κB signaling pathway

(2011) Wang   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Leptin: The Prototypic Adipocytokine and its Role in NAFLD

(2010) Claudio Procaccini et al.   CURRENT PHARMACEUTICAL DESIGN

Editorial [Hot topic: Adipocytokines in Nonalcoholic Fatty Liver Disease: Key Players Regulating Steatosis, Inflammation and Fibrosis (Executive Editor: Herbert Tilg)]

(2010) Herbert Tilg   CURRENT PHARMACEUTICAL DESIGN

Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis

(2009) Jee-Young Kim et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease

(2009) Stergios A. Polyzos et al.   DIABETES OBESITY & METABOLISM

Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity

(2009) T. Romacho et al.   DIABETOLOGIA

Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-κB pathway

(2009) W-J Lee et al.   INTERNATIONAL JOURNAL OF OBESITY

Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic β-cells

(2009) James E P Brown et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Influence of Visfatin on Histopathological Changes of Non-alcoholic Fatty Liver Disease

(2008) R. Aller et al.   DIGESTIVE DISEASES AND SCIENCES